Learn About Our Clinical Trials

Oncternal is committed to advancing our pipeline and bringing patients a new wave of novel cancer therapies. Clinical trials are an important part of that process. Both Oncternal-sponsored and investigator sponsored clinical trials are ongoing to understand the potential therapeutic benefit our product candidates might provide, to help researchers understand how to best use them, and determine the best path to ultimately gain regulatory approval.


A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies (NCT05588440)


A Clinical Study of ONCT-534 in Subjects with Relapsed or Refractory Metastatic Castration Resistant Prostate Cancer (NCT05917470)

ONCT-534 Expanded Access Policy


Study of Docetaxel Combined With Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer (NCT05156905)

Consolidation for Treatment of Patients with Detectable CLL on Venetoclax (NCT04501939)